Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-05-10
2011-05-10
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S155100, C424S156100
Reexamination Certificate
active
07939074
ABSTRACT:
A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.
REFERENCES:
patent: 0252741 (1988-01-01), None
patent: WO 87/00462 (1987-01-01), None
patent: WO 92/07075 (1992-04-01), None
patent: 99/31140 (1999-06-01), None
patent: WO 99/31140 (1999-06-01), None
Bebbington et al., “High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker,”Bio/Technology10:169-175 (Feb. 1992).
Bhuyan et al., “Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells,”Cancer Research52(2):5687-5692 (Oct. 1992).
Bleiberg, “Continuing the fight against advanced colorectal cancer: new and future treatment options,”Anti-Cancer Drugs9:1 18-28 (Jan. 1998).
Bokemeyer et al., “Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma!. Aktuelle Aspekte zur adjuvanten and palliativen Chemotherapie beim kolorektalen Karzinom,”Schweizerische Rundschau Fur Medizin Praxis86:39 1510-1516 (Sep. 1997).
Casillas et al., “Adjuvant therapy for colorectal cancer: present and future perspectives,”Diseases of the Colon and Rectum40:8 977-992 (Aug. 1997).
Chen et al., “Differences in inhibition of chromosome separation and G2arrest by DNA topoisomerase II inhibitors merbarone and VM-26,”Cancer Research55(7):1509-1516 (Apr. 1995).
Colcher et al., “A spectrum of monoclonal antibodies reactive human mammary tumor cells,”Proc. Natl. Acad. Sci. USA78(5):3199-3203 (May 1981).
Czuczman et al., “IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells,”Cancer Immunology, Immunotherapy36(6):387-396 (1993).
Elias et al., “Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma,”American Journal of Respiratory and Critical Care Medicine15:4 1114-1122 (Oct. 1994).
Ellis et al., “Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma,”The Journal of Immunology155:925-937 (1995).
Engelholm et al., “Effect of Melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice,”Experimental Cell Biology54(3):138-148 (1986).
Erba et al., “Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line,”International Journal of Cancer62(2):170-175 (Jul. 1995).
Fargion et al., “Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies,”Cancer Research46:2633-2638 (May 1986).
Fogler et al., “Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen,”Cancer Research48:6303-6308 (1988).
Greiner et al., “Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment,”Cancer Research44:3208-3214 (Aug. 1984).
Greiner et al., “Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells,”J. Clin Oncol10(5):735-746 (May 1992).
Haisma et al., “A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer,”British Journal of Cancer66:3 474-478 (Sep. 1992).
Herlyn et al., “Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies,”Proc. Natl. Acad. Sci. USA76(3):1438-1452 (Mar. 1979).
Herlyn et al., “CO 17-1A and related monoclonal antibodies: their production and characterization,”Hybridoma5(Suppl. 1):S3-S10 (1986).
Inaba et al., “Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells,”Oncology Research6(7):303-309 (1994).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature321:522 (May 1986).
Kallio et al., “Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: Cell cycle arrest and induction of aneuploidy,”Environmental&Molecular Mutagenesis29(1):16-27 (1997).
Kievit et al., “Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer,”International Journal of Cancer71:2 237-245 (Apr. 1997).
Klucar et al., “G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin,”FEBS Letters400(1):127-130 (Jan. 1997).
Laio et al., “Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas,”Human Antibody Hybridomas1(2):66-76 (1990).
Litvinow et al., “Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule,”J. Cell Biology125:437-446 (1994).
Okabe et al., “Monoclonal antibodies to surface antigens of small cell carcinoma of the lung,”Cancer Research44:5273-5278 (Nov. 1984).
Paul et al., “Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM),”Hybridoma5 Suppl:1 S171-S174 (Jul. 1986).
Reichmann et al., “Reshaping human antibodies for therapy,”Nature332:323-327 (Mar. 1988).
Riethmuller et al., “Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers,”Curr. Opin. Immun.4:647-655 (1992).
Riethmuller et al., “Monoclonal antibodies in cancer therapy,”Curr. Opin. Immun.5:732-739 (1993).
Rojas et al., “Genotoxic effects of bistratene A on human lymphocytes,”Mutation Research367(3):169-175 (Mar. 1996).
Schwartzberg, “Chemotherapy plus PANOREX (17-1A monoclonal antibody) as adjuvant therapy for colon cancer: Ongoing studies,”Cancer Investigation17Supp1:1 32-34 (1999).
Song, “Expression of sarcoma-associated antigens p102 and p200 in human sarcoma cell lines,”Anticancer Research16(3A):1171-1175 (1996).
Stephens et al., “The construction of a highly efficient and versatile set of mammalian expression vectors,”Nucleic Acid Res.17(17):7110 (1989).
Tyle, “Iontophoretic devices for drug delivery,”Pharmaceutical Research3(6):318-326 (1986).
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,”Science239:1534-1536 (Mar. 1988).
Watters et al., “Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cycloxazoline,”Cancer Chemotherapy&Pharmacology33(5):399-409 (1994).
Wei et al., “Expression of the surface antigen in human gastric cancer cells and the relation to cell cycles,”J of Oncology9(3):179-182 (1987) (Abstract).
Wulf et al., “A cell-surface apitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P,”J Cancer Research and Clinical Oncology122(8):476-482 (1996).
Ciardiello et al., Antitumor Activity of Sequential Treatment with Topotecan and Anti-epiderminal Growth Factor Receptor Monoclonal Antibody C2251, Clinical Cancer Research 5:909-916 (Apr. 1999).
Goldenberg, Trastuzumab, a Recombinant DNA-Derived Humanized Monclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer, Clinical Therapeutics 21(2):309-318 (1999).
Ishikawa et al., Antitumor Activities of a Novel Fl
Knick Vincent C.
Stimmel Julie Beth
Thurmond Linda M.
GlaxoSmithKline LLC
Han William T.
Huff Sheela J
Long William Peter
LandOfFree
Combination of an anti-EP-CAM antibody with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of an anti-EP-CAM antibody with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of an anti-EP-CAM antibody with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643977